Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.

Gastoldi S, Bresin E, Pasini A, Nardini B, Paci Della Costanza O, Sciri R, Mele C, Benigni A, Remuzzi G, Noris M, Aiello S

Open source

DOI
10.1159/000553556
Published
2026 Jul 21
Container
Nephron
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1159/000553556,
  title = {Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.},
  author = {Gastoldi S and Bresin E and Pasini A and Nardini B and Paci Della Costanza O and Sciri R and Mele C and Benigni A and Remuzzi G and Noris M and Aiello S},
  year = {2026},
  journal = {Nephron},
  doi = {10.1159/000553556},
  url = {https://doi.org/10.1159/000553556}
}

RIS

TY  - JOUR
TI  - Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.
AU  - Gastoldi S
AU  - Bresin E
AU  - Pasini A
AU  - Nardini B
AU  - Paci Della Costanza O
AU  - Sciri R
AU  - Mele C
AU  - Benigni A
AU  - Remuzzi G
AU  - Noris M
AU  - Aiello S
PY  - 2026
JO  - Nephron
DO  - 10.1159/000553556
UR  - https://doi.org/10.1159/000553556
ER  - 

APA

S, G., E, B., A, P., B, N., O, P. D. C., R, S., C, M., A, B., G, R., M, N., & S, A. (2026). Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.. Nephron. https://doi.org/10.1159/000553556

Source records